The abstract is read at the publisher; the summary is JClub's.
Diabetic kidney disease (DKD) is biologically and clinically heterogeneous, and multi-omics signatures are being used to stratify risk and mechanisms beyond glomerular filtration rate or albuminuria alone.
- Why it matters: DKD is a leading cause of kidney failure, but conventional measures miss diverse injury patterns, and clinicians must distinguish DKD from non-diabetic kidney disease for appropriate management.
- What they did: The work highlights emerging genomic, epigenomic, proteomic, and metabolomic approaches, integrating polygenic scores, data-driven clustering, and single-cell kidney atlases with deep phenotyping and biobanking.
- The result: Omics-driven precision strategies are beginning to define disease endotypes and enable actionable biomarkers and therapeutic targets, though validation, equitable representation, and clinical implementation remain key challenges.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.